Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140697 | 0.81 | NLRP3 (0.42) | MAPTALDH1A1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL4137682 | 0.74 | HPGD (0.51) | MAPTALDH1A1MAPK1KMT2AHPGD | |
| SCHEMBL25877480 | 0.73 | MAPT (0.38) | MAPTALDH1A1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL25263270 | 0.73 | DCTPP1 (0.38) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL25877386 | 0.72 | MAPK1 (0.47) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL25877483 | 0.72 | MAPT (0.43) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5333636 | 0.72 | LMNA (0.52) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL25218344 | 0.72 | ALDH1A1 (0.43) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL19260129 | 0.72 | MAPT (0.49) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL16150794 | 0.72 | ALDH1A1 (0.47) | MAPTALDH1A1MAPK1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | MAPT 3694/4885ALDH1A1 1451/4885MAPK1 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.